Sapien, OncoStem to develop cancer diagnostic test

Sapien Biosciences partners with OncoStem Diagnostics to develop breast cancer recurrence diagnostic test


OncoStem and Sapien will pilot and commercialise this test across the Apollo network

Sapien Biosciences and OncoStem Diagnostics has collaborated for the development and validation of a novel breast cancer recurrence prediction test.

OncoStem has developed a unique panel of ‘prognostic and predictive' proteomic markers that is indicative of the aggressiveness of the cancer. These markers are now being validated using retrospective tumour samples diagnosed with Stage 1, 2 or 3A breast cancer. OncoStem is collaborating with Sapien to validate this test using such annotated tumour samples with associated treatment and outcomes. Once the test is validated, OncoStem and Sapien will pilot and commercialise this test across the Apollo network.

Dr Jugnu Jain, CSO- Sapien Biosciences said, "Sapien Biosciences was set-up as a bio-repository that will enable the development of cutting-edge diagnostics & therapeutics.

The samples and associated medical data that are being systematically collated & ethically banked at Sapien are a very rich resource for the development of such novel diagnostic tests. Recurrence diagnostics in cancer is particularly dependent on the availability of reliable retrospective information which is acutely lacking in India. I am glad that Sapien is filling this huge gap and we are excited to be part of this collaboration with OncoStem to develop such a test that will represent a paradigm shift in breast cancer treatment."

"OncoStem was founded with the vision of developing novel diagnostic tests to predict cancer recurrence, an area of huge unmet medical need. This breast cancer recurrence diagnostic is the first of many such tests in development across several cancer types and is designed to predict the patients' risk of cancer recurrence within the first five years of their initial diagnosis, based on the characteristics of their tumor sample," said Dr Manjiri Bakre, CEO, OncoStem Diagnostics.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email